Study finds annual healthcare costs per patient are significantly higher than previously described– HHT costs are higher than other ...

Akebia Therapeutics®, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the ...

The 2023 AABB guidelines overall favor a restrictive transfusion strategy, recommending RBC transfusion for hemoglobin <7 ...

A new study published in the journal of BMC Nephrology showed that the effectiveness of roxadustat is comparable at varying ...

Crohn’s disease may be a lifelong condition, but today, there are an abundance of effective treatments that can help bring relief to your symptoms and reduce your risk of experiencing more serious ...

AKI - the other main type of kidney disease - can be caused by dehydration, blood loss, urinary tract obstructions such as ...

The following is a summary of “Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in ...

Treatment involves addressing ... nutritional yeast products. Pernicious anemia. Lack of intrinsic factor, B-12 can't be absorbed in the intestines. Gastric surgeries. Intestinal problems. Crohn's ...

While anemia impacts nearly a quarter of the world's population ... marked by an inability to utilize stored iron due to ...

The global anemia treatment market is on a steady growth path, with sales expected to exceed USD 10.0 billion in 2022.

Patients with symptomatic anemia associated with chronic kidney disease who are on chronic maintenance dialysis can now also ...